Processing...
Clinical Trials for Stomach Cancer
Search
Search
There are 141 active trials for advanced/metastatic stomach cancer.
Click on a trial to see more information.
141 trials meet filter criteria.
Sort by:
TrialFetch AI summary: First-line treatment for adults with unresectable/metastatic gastric, GEJ, or esophageal adenocarcinoma or squamous cell carcinoma (ECOG 0–1), testing oral IRAK4 inhibitor emavusertib (CA‑4948; targets TLR/IL‑1R→NF‑κB signaling, with FLT3/CLK activity) added to mFOLFOX7 plus PD‑1 blockade. HER2‑negative patients receive emavusertib + mFOLFOX7 + nivolumab; HER2‑positive patients receive emavusertib + mFOLFOX7 + pembrolizumab + trastuzumab.
ClinicalTrials.gov ID: NCT05187182
TrialFetch AI summary: Adults with relapsed/refractory mature B‑cell malignancies (ECOG 0–1) receive oral SGR‑1505, a MALT1 paracaspase inhibitor that suppresses BCR/BTK–NF‑κB signaling, in dose‑escalation monotherapy cohorts with planned exploratory combinations (e.g., BTK or BCL‑2 inhibitors). Excludes patients needing immediate cytoreduction or with active CNS disease.
ClinicalTrials.gov ID: NCT05544019
TrialFetch AI summary: Adults with advanced/metastatic HER2-expressing solid tumors (HER2-positive or HER2-low), including breast and gastric/GEJ cancers after standard therapies, receive IKS014, a HER2-targeting antibody–drug conjugate using a trastuzumab backbone linked to the microtubule inhibitor MMAF. Open-label dose escalation/expansion treats in 21-day cycles until progression to establish RP2D and assess antitumor activity.
ClinicalTrials.gov ID: NCT05872295
TrialFetch AI summary: Enrolling children and adolescents aged 2 to <18 years with relapsed/progressive/refractory somatostatin receptor–positive malignancies (e.g., neuroendocrine tumors, CNS tumors, lymphoma, other solid tumors) after ≥1 prior therapy, requiring SSTR expression by IHC and uptake on SSTR PET/SPECT greater than liver. Patients receive IV lutetium Lu 177 edotreotide (177Lu-DOTATOC) peptide receptor radionuclide therapy—a radiolabeled somatostatin analog targeting SSTR2 to deliver localized beta radiation—every 8 weeks for up to 6 doses (with amino acids for renal protection), either as monotherapy or after standard-of-care therapy.
ClinicalTrials.gov ID: NCT06441331
TrialFetch AI summary: Adults with centrally confirmed MTAP homozygous loss/deletion and advanced solid tumors (ECOG 0–1) who have progressed after standard therapy are enrolled in dose escalation (mesothelioma, gastroesophageal, NSCLC, urothelial), with dose-expansion limited to MTAP-deleted NSCLC after platinum chemotherapy and PD-1/PD-L1 therapy (≤3 prior lines, prior appropriate targeted therapy if actionable). Participants receive IDE892, an MTA-cooperative PRMT5 inhibitor, as monotherapy or combined with IDE397, an oral MAT2A inhibitor, in 21-day cycles.
ClinicalTrials.gov ID: NCT07277413
TrialFetch AI summary: This trial targets adult patients with advanced solid malignancies and evaluates the safety and efficacy of CRX100, an investigational immunotherapy combining autologous T cells and oncolytic vaccinia virus, as monotherapy and in combination with Pembrolizumab.
ClinicalTrials.gov ID: NCT04282044
TrialFetch AI summary: This trial investigates GSK4381562, a monoclonal antibody targeting PVRIG to enhance NK and T cell activation, as monotherapy and in combination with anticancer agents such as dostarlimab, belrestotug, nelistotug, and GSK5764227 in patients with advanced solid tumors who lack standard treatment options. Eligible participants have locally recurrent or metastatic solid tumors, have progressed after standard therapies, and possess an ECOG performance status of 0-1 with adequate organ function.
ClinicalTrials.gov ID: NCT05277051
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors—including specific expansion cohorts for RCC, NSCLC, and PD-L1-negative NSCLC—who have progressed after or cannot tolerate standard therapies or are treatment naïve for metastatic disease without actionable mutations. Patients receive STK-012, an engineered IL-2 partial agonist that selectively stimulates CD25+ T cells with reduced toxicity risk, as monotherapy or in combination with pembrolizumab, and in NSCLC, with pembrolizumab plus pemetrexed and carboplatin.
ClinicalTrials.gov ID: NCT05098132
TrialFetch AI summary: Adult patients with unresectable locally advanced or metastatic solid tumors (including melanoma, renal cell carcinoma, or PD-L1-positive NSCLC) who have progressed after or are ineligible for standard therapies receive AU-007, a novel monoclonal antibody that redirects IL-2 activity toward effector T and NK cells by blocking IL-2Rα, as monotherapy or in combination with recombinant IL-2 and/or checkpoint inhibitors. Patients must have adequate organ function, resolved prior immunotherapy toxicity, and measurable or evaluable disease.
ClinicalTrials.gov ID: NCT05267626
TrialFetch AI summary: This trial enrolls adults with metastatic or unresectable solid tumors (including NSCLC, HNSCC, HER2-negative breast, esophageal, cutaneous SCC, ovarian, bladder, cervical, pancreatic, and gastric cancers), evaluating the antibody-drug conjugate sigvotatug vedotin—targeting integrin beta-6—with or without pembrolizumab and/or platinum chemotherapy. Eligibility varies by cohort, including both treatment-naïve and previously treated/refractory patients, with fresh or recent tumor biopsy required in some arms.
ClinicalTrials.gov ID: NCT04389632